Ontology highlight
ABSTRACT:
SUBMITTER: Venugopal B
PROVIDER: S-EPMC3679738 | biostudies-other | 2013 May
REPOSITORIES: biostudies-other
Venugopal Balaji B Ansari Jawaher J Aitchison Michael M Tho Lye Mun LM Campbell Roderick R Jones Rob J RJ
BMC urology 20130521
<h4>Background</h4>Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the chromophobe subtype (chRCC) accounting for approximately 5% of all cases. The median overall survival of advanced RCC has improved significantly since the advent of tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors. However, high-quality evidence for the use of new generation tyrosine kinase inhibitors in patients with advanced chRCC is lacking. Few p ...[more]